The potential use of O6-benzylg uanine, and O6-methylguanine for the treatment of alzheimer’s disease, and t. brucei group trypanosomes infections
Annals of Systems Biology · 2022
DOI: 10.17352/asb.000018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Systems Biology, 2022. Verfasst von Penketh Philip G und 2 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Very recently we had published a paper entitled ‘The Potential Development Sulfonylhydrazines for the Treatment of Alzheimer’s Disease’ [1]. Our paper was a development from an observation by others from 1997, where a remarkable remission in Dementia was observed in cancer patients following treatment with the chemotherapeutic agent BCNU (Carmustine, 1,3-Bis(2-chloroethyl)-1-nitrosourea) [2].
Zitieren
APA
G, P. P., P, B. R., & Krishnamurthy, S. (2022). The potential use of O6-benzylg uanine, and O6-methylguanine for the treatment of alzheimer’s disease, and t. brucei group trypanosomes infections. Annals of Systems Biology. https://doi.org/10.17352/asb.000018
Vancouver
G PP, P BR, Krishnamurthy S. The potential use of O6-benzylg uanine, and O6-methylguanine for the treatment of alzheimer’s disease, and t. brucei group trypanosomes infections. Annals of Systems Biology. 2022. doi:10.17352/asb.000018
BibTeX
@article{G2022,
author = {G, Penketh Philip and P, Baumann Raymond and Krishnamurthy, Shyam},
title = {The potential use of O6-benzylg uanine, and O6-methylguanine for the treatment of alzheimer’s disease, and t. brucei group trypanosomes infections},
journal = {Annals of Systems Biology},
year = {2022},
doi = {10.17352/asb.000018}
}
EUVIMED